Abcam

Abcam Plc is a global life science company, which distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays, and other kits. The company was founded by David Douglas Cleevely, Anthony Kouzarides, and Jonathan Simon Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.

Abcam helps researches with breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annual Report and Accounts 2020 (the “Annual Report”) have been published today and are available on the Abcam plc website at www.abcamplc.com.

Abcam plc: Annual Report, Impact Report and Notice of AGM

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group's overall LTIP structure and performance framework, including proposed changes for this year's awards, it has determined to retain the existing LTIP metrics and targets contained in Abcam's current Remuneration Policy, as approved by shareholders in 2018.

News for Abcam Stock (ABCM)